目的 探討康艾注射液聯(lián)合放療治療中晚期食管癌的臨床療效，并探討其對(duì)患者免疫功能和生活質(zhì)量的影響。方法 2012年5月—2014年4月上海市閔行區(qū)中心醫(yī)院收治的中晚期食管癌患者78例，隨機(jī)分為對(duì)照組（39例）和治療組（39例），對(duì)照組采用放射治療，治療組在對(duì)照組的基礎(chǔ)上給予康艾注射液60 mL加入250 mL生理鹽水，靜脈點(diǎn)滴，1次/d，4周為1療程，兩組均連續(xù)治療2個(gè)療程。治療后，評(píng)價(jià)兩組的療效、生活質(zhì)量、細(xì)胞免疫功能。結(jié)果 治療后，治療組和對(duì)照組的總有效率分別為61.54%、56.41%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療組生活質(zhì)量（QOL）評(píng)分提高率74.36%，對(duì)照組為43.59%；治療組體質(zhì)量好轉(zhuǎn)率56.41%，對(duì)照組為33.33%，兩組比較差異均具有統(tǒng)計(jì)學(xué)意義（P<0.01）。治療后，治療組CD3⁺、CD4⁺、CD4⁺/CD8⁺、NK比例升高，CD8⁺比例下降，治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.01），治療組這些觀察指標(biāo)與對(duì)照組相比差異有統(tǒng)計(jì)學(xué)意義（P<0.01）；對(duì)照組各指標(biāo)無(wú)明顯變化，與治療前相比差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 康艾注射液聯(lián)合放療治療中晚期食管癌具有較好的臨床療效，可以提高患者的生活質(zhì)量和體質(zhì)量，減輕放療的不良反應(yīng)，具有較好的臨床應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Kangai Injection combined with radiotherapy for advanced esophageal cancer and its effect on immune function and quality of life. Methods Patients with advanced esophageal cancer were randomly divided into control (39 cases) and treatment (39 cases) groups. Patients in the control group were given radiation therapy, and patients in the treatment group were iv administered with 60 mL Kangai Injection, adding 250 mL normal saline for iv drip, once daily, 4 weeks as one course. Two groups were continuous treated for two courses. After treatment, the treatment efficacy, quality of life, and cellular immunity function were evaluated.Results After treatment, the effective rates in the treatment and control groups were 61.54% and 56.41%, respectively, with significant difference between the two groups (P < 0.05). The increasing rate of QOL in the treatment and control groups were 74.36% and 43.59%, while body weight improvement rates were 54.61% and 33.33%, and the difference was statistically significant between the two groups (P < 0.05). After treatment, CD3⁺, CD4⁺, CD4⁺/CD8⁺, and NK of the treatment group increased, CD8⁺ decreased, with statistically significant difference before and after treatment (P < 0.01). Those detection indexes were compared with control group, and difference was statistically significant (P < 0.01). The indexes of control group were not changed, compared with those before the treatment, the differences had no statistically significance. Conclusion Kangai Injection can improve the quality of life and body weight and reduce toxicity, with good clinical application value for the treatment of advanced esophageal cancer.